CD8A and neoplasm: Therapeutic blockade of this axis using monoclonal antibodies restores anti-tumor immunity by augmenting CD8+ T cell proliferation and cytokine production while reducing Treg-mediated immunosuppression (FoxP3+ cell depletion >40 %) [134].